Rykindo is a bi-weekly long-acting risperidone injection and is the first innovative therapy from Luye Pharma’s central nervous system product portfolio to be marketed in the United States.
https://www.pharmalive.com/wp-content/uploads/2023/01/LuyePharma-logo.jpg450964PR Newswirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngPR Newswire2023-01-15 05:20:382023-01-16 09:59:11FDA approves Luye Pharma’s Rykindo for the treatment of schizophrenia and bipolar 1 disorder
